{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:33:32Z","timestamp":1784824412747,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in adults in western countries. Asymptomatic patients are under clinical observation; when indication for treatment according to guidelines is met, treatment is initiated. When choosing from the numerous new treatment options, individual patient needs should be considered. To date, no instrument exists to capture these needs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methodology<\/jats:title>\n            <jats:p>The ePROM was developed based on the Patient Benefit Index (PBI) methodology which captures the importance of treatment goals as well as the achievement of these goals. The development considered the COSMIN guidelines and included semi-structured interviews with 28 patients with CLL and free-text questionnaires (<jats:italic>n<\/jats:italic>\u2009=\u200915). Data were analysed via qualitative content analysis according to Kuckartz. The PBI-CLL was finalised through an expert consensus and cognitive debriefing interviews with 14 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The content elicitation showed that the individual treatment burden and treatment goals in CLL vary considerably between patients, underlining the heterogeneity of this patient group. Patients reported disease burden in their physical constitution as well as mental burden. Many patients\u2019 main goal was to live normally and with the lowest impact possible through the CLL and its therapy. The PBI-CLL developed based on these data consists of three modules: therapy outcomes, process quality and relative treatment preferences. The cognitive debriefing interviews showed that patients find the instrument relevant, comprehensive, and comprehensible.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The PBI-CLL is the first instrument to assess patients\u2019 needs and benefits in CLL. The heterogeneity we found in patient needs and preferences underlines the importance of a modular instrument which measures treatment goals and benefits in a standardized way. The PBI-CLL shall support both patient-centred therapeutic decision making and treatment evaluation in clinical practice, as well as patient-centred benefit assessment in clinical and health care research. It should therefore be tested for its psychometric properties in a subsequent validation study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41687-025-00882-5","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T13:30:38Z","timestamp":1745933438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of a modular patient-reported outcome and experience measure on patient needs and benefits in CLL (PBI-CLL)"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-4757","authenticated-orcid":false,"given":"Beke","family":"Hester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Von","family":"Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Voigtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Blome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"882_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00108-019-00733-8","volume":"61","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Eichhorst B, Hallek M (2020) Chronische lymphatische leuk\u00e4mie (Chronic lymphocytic leukemia). Internist (Berl) 61:277\u2013287. https:\/\/doi.org\/10.1007\/s00108-019-00733-8","journal-title":"Internist (Berl)"},{"key":"882_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","volume":"391","author":"M Hallek","year":"2018","unstructured":"Hallek M, Shanafelt TD, Eichhorst B (2018) Chronic lymphocytic leukaemia. Lancet 391:1524\u20131537. https:\/\/doi.org\/10.1016\/S0140-6736(18)30422-7","journal-title":"Lancet"},{"key":"882_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.15386\/mpr-1502","volume":"93","author":"IV Papathanasiou","year":"2020","unstructured":"Papathanasiou IV, Kelepouris K, Valari C et al (2020) Depression, anxiety and stress among patients with hematological malignancies and the association with quality of life: a cross-sectional study. Med Pharm Rep 93:62\u201368. https:\/\/doi.org\/10.15386\/mpr-1502","journal-title":"Med Pharm Rep"},{"key":"882_CR4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ajh.25595","volume":"94","author":"M Hallek","year":"2019","unstructured":"Hallek M (2019) Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol 94:1266\u20131287. https:\/\/doi.org\/10.1002\/ajh.25595","journal-title":"Am J Hematol"},{"key":"882_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3238\/arztebl.2019.0041","volume":"116","author":"J von Tresckow","year":"2019","unstructured":"von Tresckow J, Eichhorst B, Bahlo J et al (2019) The treatment of chronic lymphatic leukemia. Dtsch Arztebl Int 116:41\u201346. https:\/\/doi.org\/10.3238\/arztebl.2019.0041","journal-title":"Dtsch Arztebl Int"},{"key":"882_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pathol-020712-163955","volume":"9","author":"S Zhang","year":"2014","unstructured":"Zhang S, Kipps TJ (2014) The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol 9:103\u2013118. https:\/\/doi.org\/10.1146\/annurev-pathol-020712-163955","journal-title":"Annu Rev Pathol"},{"key":"882_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma S, Rai KR (2019) Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options. Cancer 125:1432\u20131440. https:\/\/doi.org\/10.1002\/cncr.31931","journal-title":"Cancer"},{"key":"882_CR8","doi-asserted-by":"publisher","unstructured":"Parikh SA, Gale RP, Kay NE (2020) Chronic lymphocytic leukemia in 2020: a surfeit of riches? Leukemia 34:1979\u20131983. https:\/\/doi.org\/10.1038\/s41375-020-0852-7","DOI":"10.1038\/s41375-020-0852-7"},{"key":"882_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PPA.S289139","volume":"15","author":"H Le","year":"2021","unstructured":"Le H, Ryan K, Wahlstrom SK et al (2021) Oncologist and patient preferences for novel agents in First-Line treatment for chronic lymphocytic leukemia: commonalities and disconnects. Patient Prefer Adherence 15:99\u2013110. https:\/\/doi.org\/10.2147\/PPA.S289139","journal-title":"Patient Prefer Adherence"},{"key":"882_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jval.2014.10.007","volume":"18","author":"C Blome","year":"2015","unstructured":"Blome C, Augustin M (2015) Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health 18:110\u2013115. https:\/\/doi.org\/10.1016\/j.jval.2014.10.007","journal-title":"Value Health"},{"key":"882_CR11","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1182\/blood-2019-129606","volume":"134","author":"H Le","year":"2019","unstructured":"Le H, Pendergraft T, Wahlstrom SK et al (2019) Understanding clinician and patient preferences about novel agents in chronic lymphocytic leukemia. Blood 134:4730. https:\/\/doi.org\/10.1182\/blood-2019-129606","journal-title":"Blood"},{"key":"882_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M et al (2017) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the united States: findings from the MPN landmark survey. Cancer 123:449\u2013458. https:\/\/doi.org\/10.1002\/cncr.30325","journal-title":"Cancer"},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1097\/HS9.0000000000000771","volume":"6","author":"L Laurenti","year":"2022","unstructured":"Laurenti L, Gaidano G, Mauro FR et al (2022) What are the attributes prioritized in the choice of therapy in chronic lymphocytic leukemia?? A Patient-physician Cross-matching analysis of a discrete choice experiment. Hemasphere 6:e771. https:\/\/doi.org\/10.1097\/HS9.0000000000000771","journal-title":"Hemasphere"},{"key":"882_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12885-024-11927-1","volume":"24","author":"F Verghote","year":"2024","unstructured":"Verghote F, van Praet C, Berquin C et al (2024) Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice. BMC Cancer 24:160. https:\/\/doi.org\/10.1186\/s12885-024-11927-1","journal-title":"BMC Cancer"},{"key":"882_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s11136-015-1136-y","volume":"25","author":"C Blome","year":"2016","unstructured":"Blome C, Costanzo A, Dauden E et al (2016) Patient-relevant needs and treatment goals in nail psoriasis. Qual Life Res 25:1179\u20131188. https:\/\/doi.org\/10.1007\/s11136-015-1136-y","journal-title":"Qual Life Res"},{"key":"882_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11136-023-03505-y","volume":"33","author":"E Unni","year":"2024","unstructured":"Unni E, Coles T, Lavallee DC et al (2024) Patient adherence to patient-reported outcome measure (PROM) completion in clinical care: current Understanding and future recommendations. Qual Life Res 33:281\u2013290. https:\/\/doi.org\/10.1007\/s11136-023-03505-y","journal-title":"Qual Life Res"},{"key":"882_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11136-017-1718-y","volume":"27","author":"L van de Poll-Franse","year":"2018","unstructured":"van de Poll-Franse L, Oerlemans S, Bredart A et al (2018) International development of four EORTC disease-specific quality of life questionnaires for patients with hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia. Qual Life Res 27:333\u2013345. https:\/\/doi.org\/10.1007\/s11136-017-1718-y","journal-title":"Qual Life Res"},{"key":"882_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"882_CR19","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of Cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570\u2013579. https:\/\/doi.org\/10.1200\/JCO.1993.11.3.570","journal-title":"J Clin Oncol"},{"key":"882_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.leukres.2018.06.006","volume":"70","author":"AL Bryant","year":"2018","unstructured":"Bryant AL, Drier SW, Lee S et al (2018) A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia. Leuk Res 70:106\u2013116. https:\/\/doi.org\/10.1016\/j.leukres.2018.06.006","journal-title":"Leuk Res"},{"key":"882_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.critrevonc.2015.07.012","volume":"96","author":"L Cannella","year":"2015","unstructured":"Cannella L, Caocci G, Jacobs M et al (2015) Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned? Crit Rev Oncol Hematol 96:542\u2013554. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.07.012","journal-title":"Crit Rev Oncol Hematol"},{"key":"882_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00403-009-0928-8","volume":"301","author":"M Augustin","year":"2009","unstructured":"Augustin M, Radtke MA, Zschocke I et al (2009) The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 301:561\u2013571. https:\/\/doi.org\/10.1007\/s00403-009-0928-8","journal-title":"Arch Dermatol Res"},{"key":"882_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.msard.2018.12.021","volume":"28","author":"H Beckmann","year":"2019","unstructured":"Beckmann H, Augustin M, Heesen C et al (2019) Benefit evaluation in multiple sclerosis relapse treatment from the patients\u2019 perspective - Development and validation of a new questionnaire. Mult Scler Relat Disord 28:256\u2013261. https:\/\/doi.org\/10.1016\/j.msard.2018.12.021","journal-title":"Mult Scler Relat Disord"},{"key":"882_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00403-012-1256-y","volume":"304","author":"J Feuerhahn","year":"2012","unstructured":"Feuerhahn J, Blome C, Radtke M et al (2012) Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res 304:433\u2013441. https:\/\/doi.org\/10.1007\/s00403-012-1256-y","journal-title":"Arch Dermatol Res"},{"key":"882_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1398-9995.2010.02515.x","volume":"66","author":"N Franzke","year":"2011","unstructured":"Franzke N, Sch\u00e4fer I, Jost K et al (2011) A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy 66:665\u2013670. https:\/\/doi.org\/10.1111\/j.1398-9995.2010.02515.x","journal-title":"Allergy"},{"key":"882_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1024\/0301-1526\/a000687","volume":"47","author":"N Zander","year":"2018","unstructured":"Zander N, Demirel E-B, Augustin M et al (2018) Development and validation of the patient benefit index for peripheral arterial disease. Vasa 47:219\u2013226. https:\/\/doi.org\/10.1024\/0301-1526\/a000687","journal-title":"Vasa"},{"key":"882_CR27","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jdv.19229","volume":"37","author":"A Costanzo","year":"2023","unstructured":"Costanzo A, Llamas-Velasco M, Fabbrocini G et al (2023) Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol 37:2004\u20132015. https:\/\/doi.org\/10.1111\/jdv.19229","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"882_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1684\/ejd.2022.4242","volume":"32","author":"K Masuda","year":"2022","unstructured":"Masuda K, Delozier AM, Kolodsick J et al (2022) Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7 (Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7). Eur J Dermatol 32:237\u2013243. https:\/\/doi.org\/10.1684\/ejd.2022.4242","journal-title":"Eur J Dermatol"},{"key":"882_CR29","doi-asserted-by":"publisher","unstructured":"Schr\u00e4der NHB, Korte EWH, Duipmans JC et al (2021) Identifying epidermolysis Bullosa patient needs and perceived treatment benefits: an explorative study using the patient benefit index. J Clin Med 10. https:\/\/doi.org\/10.3390\/jcm10245836","DOI":"10.3390\/jcm10245836"},{"key":"882_CR30","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jdv.17109","volume":"35","author":"D Tha\u00e7i","year":"2021","unstructured":"Tha\u00e7i D, Soliman AM, Eyerich K et al (2021) Patient-reported outcomes with Risankizumab versus fumaric acid esters in systemic therapy-na\u00efve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. J Eur Acad Dermatol Venereol 35:1686\u20131691. https:\/\/doi.org\/10.1111\/jdv.17109","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"882_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","volume":"27","author":"CB Terwee","year":"2018","unstructured":"Terwee CB, Prinsen CAC, Chiarotto A et al (2018) COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res 27:1159\u20131170. https:\/\/doi.org\/10.1007\/s11136-018-1829-0","journal-title":"Qual Life Res"},{"key":"882_CR32","unstructured":"Kuckartz U (2016) Qualitative Inhaltsanalyse: Methoden, Praxis, Computerunterst\u00fctzung, 3., \u00fcberarbeitete Auflage. Grundlagentexte Methoden. Beltz Juventa, Weinheim, Basel"},{"key":"882_CR33","unstructured":"VERBI GmbH MAXQDA (2022): computer software. VERBI-SOFTWARE 2021, Berlin, Germany"},{"key":"882_CR34","unstructured":"Mokkink LB, Prinsen C, Patrick DL, Alonso J, Bouter LM, De Vet H, Terwee CB (2019) (2019, 1\u201332) COSMIN Study Design checklist for Patient-reported outcome measurement instruments. https:\/\/www.cosmin.nl\/wp-content\/uploads\/COSMIN-study-designing-checklist_final.pdf. Accessed 20 Aug 2024"},{"key":"882_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SDM, de Boer MR et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60:34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012","journal-title":"J Clin Epidemiol"},{"key":"882_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejvs.2013.10.009","volume":"47","author":"C Blome","year":"2014","unstructured":"Blome C, Augustin M, Heyer K et al (2014) Evaluation of patient-relevant outcomes of lymphedema and lipedema treatment: development and validation of a new benefit tool. Eur J Vasc Endovasc Surg 47:100\u2013107. https:\/\/doi.org\/10.1016\/j.ejvs.2013.10.009","journal-title":"Eur J Vasc Endovasc Surg"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00882-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00882-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00882-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T13:30:45Z","timestamp":1745933445000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-025-00882-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00882-5","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Ethics Commission of the UKE Psychosocial Center (LPEK-0570). All patients participating in the study provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CB and BH have received speaker honoraria and research grants from AstraZeneca. JvT has received honoraria as an advisor\/consultant for AbbVie, Amgen, AstraZeneca, Beigene, Janssen and other financial relations with AbbVie, AstraZeneca, Beigene, Lilly, Janssen, Roche. MJV has received travel grants and\/or speaker honoraria for AstraZeneca, Beigene and Johnson & Johnson. HB is employed at AstraZeneca. JR has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}